Leukodystrophies - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Leukodystrophies - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Leukodystrophies - Pipeline Review, H2 2014', provides an overview of the Leukodystrophies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leukodystrophies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leukodystrophies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leukodystrophies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Leukodystrophies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Leukodystrophies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leukodystrophies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leukodystrophies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leukodystrophies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Leukodystrophies Overview 6
Therapeutics Development 7
Pipeline Products for Leukodystrophies - Overview 7
Pipeline Products for Leukodystrophies - Comparative Analysis 8
Leukodystrophies - Therapeutics under Development by Companies 9
Leukodystrophies - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Leukodystrophies - Products under Development by Companies 12
Leukodystrophies - Companies Involved in Therapeutics Development 13
ArmaGen Technologies, Inc. 13
Fate Therapeutics, Inc. 14
GlaxoSmithKline plc 15
Phenomenome Discoveries, Inc. 16
ReGenX Biosciences, LLC 17
Shire Plc 18
Leukodystrophies - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AGT-183 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
FT-1050 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GSK-2696274 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PPI-1011 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SHP-611 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Leukodystrophies - Recent Pipeline Updates 35
Leukodystrophies - Dormant Projects 38
Leukodystrophies - Discontinued Products 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products under Development for Leukodystrophies, H2 2014 7
Number of Products under Development for Leukodystrophies - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Leukodystrophies - Pipeline by ArmaGen Technologies, Inc., H2 2014 13
Leukodystrophies - Pipeline by Fate Therapeutics, Inc., H2 2014 14
Leukodystrophies - Pipeline by GlaxoSmithKline plc, H2 2014 15
Leukodystrophies - Pipeline by Phenomenome Discoveries, Inc., H2 2014 16
Leukodystrophies - Pipeline by ReGenX Biosciences, LLC, H2 2014 17
Leukodystrophies - Pipeline by Shire Plc, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Leukodystrophies Therapeutics - Recent Pipeline Updates, H2 2014 35
Leukodystrophies - Dormant Projects, H2 2014 38
Leukodystrophies - Discontinued Products, H2 2014 39